Core Viewpoint - Indian pharmaceutical stocks experienced a decline of 2.6% following the announcement of a 100% tariff on branded and patented drugs by U.S. President Donald Trump, which is set to take effect on October 1 [1] Industry Impact - The announcement of the tariff is expected to significantly impact the Indian pharmaceutical sector, which relies heavily on exports to the U.S. market [1] - The 100% tariff could lead to increased costs for Indian pharmaceutical companies, potentially affecting their profit margins and competitiveness in the U.S. [1]

Core Viewpoint - Starting from October 1, 2025, U.S. President Trump will impose a 100% tariff on any brand or patented pharmaceutical products unless companies are establishing their manufacturing facilities in the U.S. [1] Group 1 - The announcement indicates a significant shift in U.S. trade policy towards the pharmaceutical industry, aiming to incentivize domestic manufacturing [1] - U.S. stock futures experienced slight fluctuations following the announcement, while the U.S. dollar index saw a minor increase [1]